Form 4: Silexion Director Lushi Boosts Indirect Stake

Silexion Therapeutics Director Avner Lushi indirectly acquired 9,091 ordinary shares and 10,685 stock options through Guangzhou Sino-Israel Biotech Fund for director services.

Summary

• Avner Lushi, a Director of Silexion Therapeutics Corp (SLXN), indirectly acquired 9,091 ordinary shares and 10,685 stock options through Guangzhou Sino-Israel Biotech Fund (GIBF).
• The 9,091 ordinary shares were granted as fully vested restricted share units (RSUs) on February 20, 2026, immediately settled for shares, with a transaction price of $0.
• The 10,685 stock options, with an exercise price of $1.65, were also granted on February 20, 2026, for director services.
• These options vest entirely on February 12, 2027 (one-year anniversary of grant approval) and expire on February 12, 2036 (ten-year anniversary).
• Lushi disclaims beneficial ownership except to the extent of his indirect pecuniary interest, as he serves as a Managing Partner and CEO of GIBF.
• An additional 1,872 stock options, granted on February 9, 2026, with an exercise price of $18.9 and expiring on February 9, 2035, are reported for informational purposes only, with no transactions effected.
• Following these transactions, Lushi indirectly beneficially owns 25,399 ordinary shares and a total of 12,557 stock options (10,685 + 1,872) through GIBF.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director is increasing their indirect stake in the company through compensation, aligning their interests with shareholders. The grants are routine but demonstrate continued engagement.

Positives

• Director Avner Lushi received a grant of 9,091 fully vested restricted share units, immediately settled into ordinary shares, indicating compensation for services.
• Lushi also received a grant of 10,685 stock options with an exercise price of $1.65, aligning his interests with long-term company performance.
• The grants were approved by the Issuer's board of directors, suggesting internal confidence in the compensation structure.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Management Comments

• The Reporting Person disclaims beneficial ownership of the securities reported in this row except to the extent of his indirect pecuniary interest therein.

Industry Context

StockSavvy.ai notes that director compensation often includes equity grants like RSUs and stock options, which are standard practices to align management and director interests with shareholder value creation. These grants are typical for directors providing services to biotech companies like Silexion Therapeutics.

Comparison to Industry Standards

• The grant of fully vested restricted share units and stock options as compensation for director services is a common practice across various industries, including biotechnology.
• Companies such as Moderna (MRNA) and BioNTech (BNTX) frequently use equity-based compensation to attract and retain top talent and directors, aligning their incentives with long-term company performance.
• The exercise price of $1.65 for the newly granted options is significantly lower than the $18.9 exercise price of previously reported options, which could indicate a lower current market valuation or a strategic incentive for future growth.

Corporate Governance

Related Party Transactions

• The grant of ordinary shares and stock options was made to Guangzhou Sino-Israel Biotech Fund (GIBF), where the reporting person, Avner Lushi, serves as a Managing Partner and CEO. This constitutes a related party transaction as Lushi has indirect pecuniary interest and shared voting/investment authority through GIBF.

Stakeholder Impact

• Shareholders: The increase in indirect beneficial ownership by a director may be viewed positively as it aligns management interests with shareholder value. However, the grants dilute existing shares slightly over time.

Next Steps

• The 10,685 stock options will vest in their entirety on February 12, 2027.

Key Dates

Recommendation

While the director's increased indirect stake through equity compensation is a positive signal of alignment, Form 4 filings primarily report routine insider transactions rather than fundamental business performance or strategic shifts. The grants are part of a compensation package and do not inherently suggest a significant undervaluation or overvaluation of the stock, warranting a "hold" recommendation for seasoned investors awaiting more comprehensive financial or operational updates.

Keywords

Silexion Therapeutics, SLXN, Avner Lushi, Director, Form 4, Insider Trading, Stock Options, Restricted Share Units, RSU, Beneficial Ownership, Corporate Governance, Guangzhou Sino-Israel Biotech Fund